EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial

@article{Rice2014EMA401AO,
  title={EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial},
  author={A S C Rice and Robert H. Dworkin and Tom D McCarthy and Praveen Anand and for the EMA401-003 study group},
  journal={The Lancet},
  year={2014},
  volume={383},
  pages={1637-1647}
}
BACKGROUND Existing treatments for postherpetic neuralgia, and for neuropathic pain in general, are limited by modest efficacy and unfavourable side-effects. The angiotensin II type 2 receptor (AT2R) is a new target for neuropathic pain. EMA401, a highly selective AT2R antagonist, is under development as a novel neuropathic pain therapeutic agent. We assessed the therapeutic potential of EMA401 in patients with postherpetic neuralgia. METHODS In this multicentre, placebo-controlled, double… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 44 extracted citations

Emerging drugs for neuropathic pain.

Expert opinion on emerging drugs • 2014
View 4 Excerpts
Highly Influenced

Angiotensin II Triggers Peripheral Macrophage-to-Sensory Neuron Redox Crosstalk to Elicit Pain.

The Journal of neuroscience : the official journal of the Society for Neuroscience • 2018
View 3 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…